



DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service
National Institutes of Health

Memorandum

Date July 24, 1986

From Betty J. Abbott, Biologist,
Biological Testing Branch, DTP, DCT, NCI

Subject Replacement of 3M531 in Tumor Panel

To Screeners 03, 08, 09 and 28
Battelle, So. Res. Inst., IITRI, Inst. Jules Bordet

Effective immediately, Dr. Boyd, Associate Director for the DTP, has authorized the replacement of the M5076 Sarcoma (3M531) with the A-549 human lung Adenocarcinoma subrenal capsule assay (3LNG5).


Criteria for activity for the 3LNG5 are as follows:

T/C between 1 and 20 = MC-1 criteria
T/C ≤ 0 = DN-2 criteria

It should be noted that a T/C of 0 is required for tumor stasis and a T/C of -99 is required to produce a two log cell kill.

No new materials are to be tested in the 3M531. Please provide us with a list of my compounds on hand which were previously scheduled for this tumor system but have not yet gone on test so that we may reschedule for 3LNG5 as feasible.

Instruction #387


Betty J. Abbott

BJA:kg

cc: Dr. ~~Boyd~~
✓ Ms. Brackett
Ms. Donovan
Mr. Dykes
Mr. Greenberg
Dr. Mayo
Mr. Miller
Dr. Plowman
Dr. Shoemaker
Ms. Simpson-Herren
Dr. Waters
Dr. Wolpert